Compare TDOC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | JANX |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.3M | 790.3M |
| IPO Year | 2015 | 2021 |
| Metric | TDOC | JANX |
|---|---|---|
| Price | $5.94 | $15.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $7.56 | ★ $48.73 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | $10,000,000.00 |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $12.12 |
| 52 Week High | $9.77 | $35.34 |
| Indicator | TDOC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 58.56 |
| Support Level | $5.01 | $13.10 |
| Resistance Level | $8.91 | $15.49 |
| Average True Range (ATR) | 0.28 | 0.64 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 76.38 | 45.26 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.